Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement - Genmab A/S held its Annual General Meeting on March 19, 2026, where the Board of Directors was constituted, appointing Ms. Deirdre P. Connelly as Chair and Ms. Pernille Erenbjerg as Deputy Chair [1] - The company decided to grant 5,213 restricted stock units and 4,485 warrants to employees and subsidiaries [1] Restricted Stock Units - Each restricted stock unit is awarded cost-free and provides a conditional right to receive one share of Genmab A/S, with a fair value of DKK 1,645.00 per unit [2] - The restricted stock units will vest three years after the grant date, subject to specific vesting conditions [3] Warrants - Each warrant is also awarded cost-free, with an exercise price of DKK 1,645.00, allowing the owner to subscribe to one share of nominally DKK 1 [4] - The fair value of each warrant is calculated at DKK 530.62 using the Black-Scholes formula, and they will vest three years after the grant date, expiring at the seventh anniversary of the grant date [5] Company Overview - Genmab is an international biotechnology company focused on developing innovative antibody medicines for cancer and other serious diseases, with over 25 years of experience [6] - The company has a strong late-stage clinical pipeline and has advanced a range of antibody-based therapeutic formats, including bispecific antibodies and antibody-drug conjugates [6] - Established in 1999, Genmab is headquartered in Copenhagen, Denmark, and has a presence in North America, Europe, and Asia Pacific [7]